Physician profile
Walter O Ramirez
NPI 1992719074
$2,547.47
in general payments reported to CMS, 2019-2025
11 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.70 · 2020: $176 · 2021: $655 · 2022: $144 · 2023: $757 · 2024: $546 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,707.66 | 2020-2024 | Gallant, Aveir, Mitraclip |
| Philips North America LLC | $359.84 | 2023-2025 | Diagnostic Ecg Service, (Ck4) Mcot |
| Heartflow, INC. | $148.46 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $68.57 | 2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $64.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.82 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.03 | 2019-2022 | |
| Edwards Lifesciences Corporation | $41.59 | 2021 | |
| Impulse Dynamics (USA) INC. | $26.17 | 2022 | |
| Amgen INC. | $21.36 | 2025 | Repatha |
| Pfizer INC. | $20.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.